Open Government Portal
The goal of this qualitative research is to gain an understanding of the collective impacts that women's Healing Lodges have on Indigenous offenders, as well as the challenges that are currently facing the operation of these sites.
This research aims to examine the effectiveness of the Onboarding Program through the consideration of its impact on both Correctional Officers (Cos) and on the broader institutional environment.
Opioid agonist treatment (OAT) is an effective intervention for the care of persons with opioid use disorder (OUD). Previous studies show that maintaining OAT not only contributes to reducing the number of overdoses but also addresses the health needs of the general and mainstream population.
On any given day, roughly 500 offenders who were conditionally released from federal custody are deemed to be unlawfully at large (UAL). While recent studies have examined the general profile of all UAL offenders, the purpose of this study is to explore differences between those who are UAL whereupon their sentence has not yet expired with those who are still UAL and reached a sentence expiration date.
Opioid agonist treatment (OAT) is an effective treatment for opioid use disorder (OUD) as it prevents withdrawal symptoms, reduces cravings, and has been associated with beneficial outcomes such as reductions in illicit drug use and related harms (e.g., overdose, mortality, etc.). To better understand OAT-related experiences and release-related perspectives among federal offenders with OUD, we conducted the current longitudinal mixed-methods study. Please note that this report is a one page summary. If you wish to have a copy of the full report, please send a request comment via the Open Government Portal or email the OG team: firstname.lastname@example.org.
Correctional populations experience high levels of opioid use disorder (OUD) and increased risks for related harms upon the high-risk period of community release and reintegration, including overdose and premature mortality. Opioid agonist therapy (OAT) is an effective treatment for OUD and its provision is associated with a reduction in these and other related risks during the community transition period.Please note that this report is a one page summary. If you wish to have a copy of the full report, please send a request comment via the Open Government Portal or email the OG team: email@example.com.
Presents FINTRAC’s results, activities and operations for 2022–23
This guidance document addresses the development of contraceptive products, intended for use by women during their reproductive years, which contain sex steroids as active ingredient(s).
These guidelines have been developed by a Therapeutic Products Programme's Working Group for the Toxicological Assessment of Contraceptive Steroids in close consultation with several experts in the fields of toxicology, pathology and reproductive physiology.
This guidance has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. The ICH Steering Committee has endorsed the final draft and recommended its adoption by the regulatory bodies of the European Union, Japan and USA.